福沙吡坦dimeglumine(阿瑞吡坦)115mg/vial,150mg/vial;冻干重组后的第四和稀释输液密码;含有聚山梨酯80。 法律分类: 接收 类药物注射的校订 P物质/神经激肽-1受体拮抗剂。 制造商校订注射液 默克制药公司 适应症校订注射 与其他止吐药物合用,以防止急性和​​延迟性恶心和呕吐中等初次和重复的课程相关的高度致吐性癌症化疗,包括高剂量顺铂。 成人注射剂量校订 ≥18yrs:给糖皮质激素和5 - HT3受体拮抗剂(见文献)。给约。在化疗前30分钟。高致吐性:单剂量方案:20 -第1天30分钟为150mg四。中度或高度致吐:3天疗程:115mg四,超过15分钟第1天,然后天2和3:一次口服80毫克,在每天上午。 儿童注射剂量为校订 “18yrs:不推荐。 另外: 订正 禁忌的校订注射 伴随匹莫齐特,西沙必利。 警告/注意事项的订正注射 不适合长期连续使用。严重肝功能不全。妊娠(Cat.B)。哺乳母亲:不推荐。 互作校订注射 见禁忌。监视器,和慎重,CYP3A4的底物,包括化疗药物(如异环磷酰胺,长春碱,长春新碱); CYP3A4抑制剂(如氮唑类抗真菌,大环内酯类,奈法唑酮,利托那韦,奈非那韦,地尔硫),以及与CYP3A4的诱导剂(如卡马西平,苯妥英钠,利福平)。 Potentiates地塞米松(减少50%的剂量),甲泼尼龙(减少25%和50%的口服剂量的静脉注射),咪唑安定,阿普唑仑,三唑仑。可对抗华法林(密切留意每个疗程开始后2周卢比);苯妥英,甲苯磺丁脲,其他CYP2C9的底物;帕罗西汀,(使用1个月,期间和之后,最后一剂的替代或备份方法)口服避孕药。
注射液不良反应的校订 无力,疲劳,打嗝,谷丙转氨酶/ AST的升高,头痛,便秘,厌食,胃肠不适,嗳气,低血压,皮肤瘙痒,发热。注射:已经来到部位疼痛。
【原产地英文商品名】Emend 150MG/10mls/vial 【原产地英文药品名】FOSAPREPITANT DIMEGLUMINE 【中文参考商品译名】 注:以下产品不同规格和不同价格,购买时请以电话咨询为准! ·Emend 150毫克/10毫升/瓶 ·Emend 115毫克x1针瓶 【中文参考药品译名】福沙吡坦二甲葡胺 【生产厂家中文参考译名】美国默克 【生产厂家英文名】Merck
FDA支持批准抗呕吐药Emend 默克公司预防化疗病人恶心和呕吐的实验性药物Emend今天得到了FDA顾问组的关键支持,这意味着该药很可能被批准在美国销售。 这些专家告诉FDA,Emend减少恶心、呕吐发作的效果好于现有药物。这样,很少反对专家小组建议的FDA很可能与这家总部在新泽西的公司碰面,以准备认可的最终详细资料。 专家组全都投票赞成该药的安全性和有效性,但反对批准它用于多种化疗药,而只应用于默克公司研究得最多的:葛兰素史克公司的Navelbine,及勃列斯多·迈耶公司的紫杉醇、顺铂和Etopophos。尽管专家们建议了这一限制,但医生可以因任何用途开具本药。
Emend主要是在大脑后部而不是肠道来起作用,可与其它常用抗呕吐药联用。默克公司要求批准它在化疗后立即用来预防呕吐和恶心,直至化疗后五天。如果得到批准,它将是这类新药中的第一种,而且是唯一一种化疗后几天治疗呕吐的药物。 Generic Name for EMEND INJECTION Fosaprepitant dimeglumine (prodrug of aprepitant) 115mg/vial, 150mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains polysorbate 80. Legal Classification: Rx Pharmacological Class for EMEND INJECTION Substance P/neurokinin 1 receptor antagonist. Manufacturer of EMEND INJECTION Merck & Co., Inc. Indications for EMEND INJECTION In combination with other antiemetic agents to prevent acute and delayed nausea andvomitingassociatedwithinitialandrepeatcoursesofmoderatelytohighlyemetogenic cancer chemotherapy, including high-dose cisplatin. Adult dose for EMEND INJECTION ≥18yrs: Give with corticosteroid and 5-HT3 antagonist (see literature). Give approx. 30min prior to chemotherapy. Highly emetogenic: Single-dose regimen: 150mg IV over 20–30min on Day 1. Moderately or highly emetogenic: 3-Day regimen: 115mg IV over 15 min on Day 1, then Days 2 and 3: 80mg orally once daily in the AM. Children's dosing for EMEND INJECTION <18yrs: not recommended. Also: EMEND Contraindications for EMEND INJECTION Concomitant pimozide, cisapride. Warnings/Precautions for EMEND INJECTION Not for chronic continuous use. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended. Interactions for EMEND INJECTION See Contraindications. Monitor, and caution with, CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine); CYP3A4 inhibitors (eg, azole antifungals, macrolides, nefazodone, ritonavir, nelfinavir, diltiazem); and with CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its doseby50%),methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each regimen); phenytoin, tolbutamide, other CYP2C9 substrates; paroxetine, oral contraceptives (use alternative or backup method during and for 1 month after last dose). Adverse Reactions for EMEND INJECTION Asthenia, fatigue, hiccups, ALT/AST increased, headache, constipation, anorexia, GI upset, eructation, hypotension, pruritus, pyrexia. Injection: inj site pain. How is EMEND INJECTION supplied? Caps 40mg—1; Bi-fold pack (2 x 80mg)—1; Tri-fold pack (1 x 125mg + 2 x 80mg)—1; Vial—1 |